Introduction
As continuous subcutaneous insulin infusion (CSII) usage to aid diabetes management becomes more widespread, there is still uncertainty regarding its effectiveness and safety. RCTs reported small improvements in HbA
1c post-CSII initiation; before/after studies suggested larger effects [
1]. Several studies reported a reduction in severe hypoglycaemia rates [
1‐
3]. The effect of CSII on diabetic ketoacidosis (DKA) is unclear as studies conflict in direction of effect reported [
2‐
4].
Criteria for CSII initiation differ across countries [
5]. CSII therapy initiation in Scotland follows criteria set by the National Institute for Health and Care Excellence (NICE) guidelines [
6], Scottish Government policy and individual National Health Service (NHS) health board budget allocation decisions. A recent study [
7] examined the effect of CSII therapy on HbA
1c among people with type 1 diabetes in the Scottish health board Lothian and found a significant decrease in HbA
1c following CSII initiation, particularly among those with suboptimal glycaemic control. In this paper, we widen the scope of that analysis by focusing on CSII therapy initiation in people with type 1 diabetes throughout Scotland.
Our aim was to: (1) describe the current prevalence of ever-CSII use; and (2) assess the effect of CSII therapy on glycaemic control as measured by HbA1c, DKA and severe hospitalised hypoglycaemia (SHH). We furthermore explored differences in CSII therapy effect across baseline HbA1c bands and sociodemographic strata (age band at CSII initiation, sex, area-level deprivation).
Discussion
We investigated the current prevalence of CSII usage among the Scottish population with type 1 diabetes. We studied the association of CSII therapy with HbA1c levels, DKA and SHH event-rates. Prevalence of CSII usage is relatively low, but growing, and varies substantially across sociodemographic strata. CSII therapy was associated with a reduction in HbA1c, which was sustained through time for at least 5 years. The greatest reductions were seen in those with the highest baseline HbA1c levels. Effects of exposure did not vary across SIMD quintiles (but CSII prevalence did), while sustained reductions of varying magnitude were seen across sex and age bands, apart from in adolescents. Comparisons with adolescent non-users nonetheless suggested an improvement with CSII in this group. CSII was associated with an overall reduction in DKA rate but the magnitude and direction of effect varied across sociodemographic strata. CSII was associated with an overall reduction in SHH rate.
CSII therapy is generally not funded out-of-pocket in Scotland. There has been a significant increase in CSII provision across the country in the last 8 years in line with a nationwide effort to support the availability of CSII. Variability of usage across sociodemographic strata followed similar patterns to other countries: van den Boom et al. [
18] reported higher usage within younger age bands in the Diabetes Patienten Verlaufsdokumentation (DPV) cohort. The National Diabetes Insulin Pump Audit [
19] (England, Wales) 2017–2018 reported a higher pump-use prevalence in women and in those from less deprived areas. Findings from a qualitative study by Scott et al. [
20] highlighting higher access barriers to intensive insulin regimen (including CSII therapy) for people from lower socioeconomic groups are reflected in our observation that CSII prevalence is lower among the most deprived.
Within-person changes observed in our national study following CSII initiation were comparable in direction and magnitude to those reported regionally in NHS Lothian [
7]. We found the CSII therapy package to be independently associated with a significant fall in HbA
1c. Magnitude and direction of estimated changes are similar to those reported in before/after studies of patients switching from multiple daily injections (MDI) to CSII in Pickup and Sutton’s meta-analysis [
1]: −0.72% (−7.9 mmol/mol). Our findings are in line with those from other local-scale UK studies which reported improvements in glycaemic control following CSII initiation to be sustained at least up to 5 to 6 years [
7,
21,
22]. While diabetes care in Scotland has improved in the past decade, the stability of HbA
1c in the matched non-user sample supports conclusions that observed reductions among pump users are associated with CSII-package and not explained by the secular trend of HbA
1c improvement.
In line with previous findings, those with the highest baseline HbA
1c benefited most from CSII. NHS Lothian reported a −22.2 mmol/mol change in those starting with HbA
1c ≥ 85 mmol/mol and the meta-analysis showed a mean difference (MDI vs CSII) greater than 16 mmol/mol for those with baseline HbA
1c ≥ 80 mmol/mol [
1,
23]. Hence, CSII helps individuals transition from higher to lower complication-risk HbA
1c groups. The slight increase in HbA
1c in those with baseline levels <54 mmol/mol is unsurprising as it is likely that this group would have been prescribed CSII to reduce hypoglycaemia.
Differences observed across sex strata were similar to previous findings [
7,
24].
Patterns in HbA
1c among those starting a pump in their teenage years were similar to those described by Johnson et al. in their long-term paediatric CSII outcome study (median age 11.5 years) [
2]. In their study, after an initial decrease, HbA
1c started increasing but remained lower than levels of matched control participants on MDI, and differences remained significant for 7 years. Our study’s matched differences stopped being significant after 4 years, likely due to our group including older individuals, who, after adolescence, transition into a phase of more stable glycaemic control, whereas participants in the study by Johnson et al. were censored when they transitioned to adult services. Related to this, the higher reductions among the 19–24 years age band are likely due to a combination of glycaemic control tending to stabilise at lower levels beyond adolescence, and CSII use.
Although the sample size was small, we found that CSII was beneficial in those initiating CSII after prior flash monitoring/CGM usage.
We found CSII to be associated with a reduced overall DKA rate, whereas previous findings have been conflicting. A meta-analysis [
25] suggested that CSII was associated with higher DKA rates in older studies (before 1993). Pickup and Keen [
26] noted that modifiable factors such as patient/healthcare provider inexperience can increase the likelihood of DKA around the beginning of CSII use, as ketosis occurs rapidly following insulin interruption due to use of rapid-acting insulin in CSII devices [
4], but we found no increase of crude DKA rates within the first year of usage.
More recent studies have been inconclusive. Some paediatric studies reported decreases, and others reported increases [
2‐
4,
27]. Thomas et al. [
28] identified CSII as a predictor of DKA in adults from the FinnDiane cohort. Different follow-up times, DKA definitions (e.g. pH/bicarbonate-based) and cohort characteristics (adults/children) could partially explain the differing findings between studies. This variability is reflected within our study by the difference in the direction of estimates across age bands, with rate increase in the 45–64 years age band, for example.
The increase in risk of DKA with deprivation levels in Scotland was highlighted by Govan et al. [
29]. Shulman et al. [
30] reported worse outcomes in those from lower socioeconomic status in a Canadian paediatric study of pump users. However, our findings show that although DKA rates remain higher in more vs less deprived areas in post-pump person-time, they were generally lower in post- vs pre-pump person-time. Where differences were not significant, rates did not increase post-pump.
Since recurrent DKA is an exclusion criterion for pump therapy in Scotland, our conclusions pertain to a group of people with type 1 diabetes who have a lower pre-exposure propensity to DKA and may not generalise to those with a higher baseline DKA propensity. It is crucial to understand the mechanisms behind the observed reduction in DKA.
Several studies [
1‐
3] have shown an association of CSII with a reduction in severe hypoglycaemia rate (a 4.34 rate-reduction factor was reported by Pickup and Sutton [
1]). Crude SHH rates were lower in CSII-exposed vs non-exposed person-time, and the modelled estimate was consistent with an improvement in SHH following CSII-package. However, our findings are not comparable to other studies, which captured severe hypoglycaemia events requiring third-party assistance, whereas our definition was limited to hospital admissions, missing any events treated in the community.
Acknowledgements
We thank the SDRN Epidemiology Group: J. Chalmers (Diabetes Centre, Victoria Hospital, Kirkcaldy, UK), C. Fischbacher (Information Services Division, NHS National Services Scotland, Edinburgh, UK), B. Kennon (Queen Elizabeth University Hospital, Glasgow, UK), G. Leese (Ninewells Hospital, Dundee, UK), R. Lindsay (British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK), J. McKnight (Western General Hospital, NHS Lothian, Edinburgh, UK), J. Petrie (Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK), R. McCrimmon (Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK), S. Philip (Grampian Diabetes Research Unit, Diabetes Centre, Aberdeen Royal Infirmary, Aberdeen, UK), D. McAllister (Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK), E. Pearson (Population Health and Genomics, School of Medicine, University of Dundee, Dundee, UK) and S. Wild (Usher Institute, University of Edinburgh, Edinburgh, UK).
Some of the data were presented as an abstract (poster presentation) at the 56th EASD Annual Meeting in 2020.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.